Data From Two Studies Demonstrating Financial Impact Of INPEFA To Be Presented At The Academy Of Managed Care Pharmacy Nexus 2023 National Meeting
Portfolio Pulse from Benzinga Newsdesk
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) highlighted two studies demonstrating the positive financial impact of INPEFA (sotagliflozin), recently approved by the FDA for heart failure treatment. The studies, presented at the Academy of Managed Care Pharmacy Nexus 2023 National Meeting, showed that while INPEFA increased pharmacy costs, it reduced medical costs due to lower readmission rates and fewer emergency department visits. The studies also concluded that INPEFA is a cost-effective treatment for heart failure among patients with type 2 diabetes.
October 17, 2023 | 8:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Lexicon Pharmaceuticals' INPEFA shows positive financial impact in studies, reducing medical costs despite increased pharmacy costs. This could potentially boost the company's revenues and reputation in the market.
The studies show that INPEFA, despite increasing pharmacy costs, reduces overall medical costs due to lower readmission rates and fewer emergency department visits. This could lead to increased adoption of the drug by healthcare providers, potentially boosting Lexicon's revenues. The positive results also enhance the company's reputation for producing effective and cost-efficient drugs.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100